Phibro Animal Health (PAHC) just unveiled an announcement.
Phibro Animal Health Corporation has struck a deal to acquire Zoetis Inc.’s medicated feed additive and water soluble product lines, with the transaction including the purchase of equity interests in Zoetis Medolla and Zoetis Suzhou. The $350 million deal, subject to adjustments, will be financed primarily through a $325 million debt facility arranged with Rabobank, Compeer, and Citibank, alongside potential balance sheet cash. The acquisition is dependent on standard regulatory approvals and the fulfillment of other customary closing conditions.
For a thorough assessment of PAHC stock, go to TipRanks’ Stock Analysis page.
